- Home
- IMAB vs SWZ Comparison
IMAB vs SWZ Comparison
Compare IMAB & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- SWZ
- Stock Information
- Founded
- IMAB 2014
- SWZ 1986
- Country
- IMAB United States
- SWZ United States
- Employees
- IMAB N/A
- SWZ N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- SWZ Finance Companies
- Sector
- IMAB Health Care
- SWZ Finance
- Exchange
- IMAB Nasdaq
- SWZ Nasdaq
- Market Cap
- IMAB 73.9M
- SWZ 82.2M
- IPO Year
- IMAB 2020
- SWZ N/A
- Fundamental
- Price
- IMAB $2.50
- SWZ $6.26
- Analyst Decision
- IMAB Strong Buy
- SWZ
- Analyst Count
- IMAB 2
- SWZ 0
- Target Price
- IMAB $5.50
- SWZ N/A
- AVG Volume (30 Days)
- IMAB 1.0M
- SWZ 14.2K
- Earning Date
- IMAB 05-15-2025
- SWZ 01-01-0001
- Dividend Yield
- IMAB N/A
- SWZ 6.59%
- EPS Growth
- IMAB N/A
- SWZ N/A
- EPS
- IMAB N/A
- SWZ N/A
- Revenue
- IMAB N/A
- SWZ N/A
- Revenue This Year
- IMAB N/A
- SWZ N/A
- Revenue Next Year
- IMAB N/A
- SWZ N/A
- P/E Ratio
- IMAB N/A
- SWZ N/A
- Revenue Growth
- IMAB N/A
- SWZ N/A
- 52 Week Low
- IMAB $0.60
- SWZ $7.12
- 52 Week High
- IMAB $3.08
- SWZ $8.57
- Technical
- Relative Strength Index (RSI)
- IMAB 67.42
- SWZ 38.88
- Support Level
- IMAB $2.29
- SWZ $6.25
- Resistance Level
- IMAB $2.69
- SWZ $6.37
- Average True Range (ATR)
- IMAB 0.35
- SWZ 0.06
- MACD
- IMAB 0.00
- SWZ 0.03
- Stochastic Oscillator
- IMAB 64.53
- SWZ 8.75
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.